Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2004-10-27
2009-12-15
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S189000, C514S624000
Reexamination Certificate
active
07632972
ABSTRACT:
Compounds and related methods for synthesis, and the use of compounds and combination therapies for the treatment of cancer and modulation of apoptosis in cells are disclosed. The generation of synthetic combinatorial libraries and the evaluation of library member compounds regarding induction of apoptosis selectively in cancer cells are disclosed. Compounds, methods of making the compounds, and therapeutic methods with application against breast cancer cells, melanoma cancer cells, colon cancer cells, and other cancer cells are described.
REFERENCES:
patent: 3360432 (1967-12-01), Spano et al.
patent: 4301021 (1981-11-01), Breant
patent: 5118845 (1992-06-01), Peck et al.
patent: 5569673 (1996-10-01), Morre et al.
patent: 5708020 (1998-01-01), Langlois et al.
patent: 5852194 (1998-12-01), Lantzsch
patent: 6121488 (2000-09-01), Nikam
patent: 6444638 (2002-09-01), Schwartz et al.
patent: 6548536 (2003-04-01), Hara et al.
patent: 6605589 (2003-08-01), Uckun et al.
patent: 6608026 (2003-08-01), Wang et al.
patent: 6627623 (2003-09-01), Ho et al.
patent: 2003/0148966 (2003-08-01), Jayaram et al.
patent: 2003/0176506 (2003-09-01), Dawson et al.
patent: 2003/0198949 (2003-10-01), Goldmakher et al.
patent: 1520070 (1968-04-01), None
McQuade et al, J. Am. Chem. Soc., 1997, 119, 8528-8532.
Kuehne et al, Journal of Organic Chemistry, 1977, 42(12) 2082-2087.
Shiina et al, Tetrahedron Letters, 44 (2003) 1951-1955.
Kunishima, M. et al., “Formation of carboxamides by direct condensation of carboxylic acids and amines in alcohols using a new alcohol- and water- soluble condensing agent: DMT-MM,” Tetrahedron 47:1551-1558, 2001.
Kunishima, M. et al., “Approach to green chemistry of DMT-MM: recovery and recycle of coproduct to chloromethane-free DMT-MM,” Tetrahedron Letters 43:3323-3326, 2002.
PCT International Search Report for International Application No. PCT/US04/35746, dated Jun. 27, 2005, 4 pages.
Adjei, A. A. et al., “Novel Anticancer Agents in Clinical Development,” Cancer Biol. Ther. S1:S5-S15, 2003 (abstract).
Alley, M. C. et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay,” Cancer Research 48:589-601, Feb. 1, 1988.
Anderson, C. M. et al., “Systemic Treatment for Advanced Cutaneous Melanoma” Oncology, 9:1149-1154, 1995 (abstract).
Blake, C. A. et al., “Estrogen Can Protect Splenocytes from the Toxic Effects of the Environmental Pollutant 4-tert-Octylphenol,” Endocrine 6(3):243-249, Jun. 1997.
Blatt, N. B. et al., “Signaling Pathways and Effector Mechanisms Pre-Programmed Cell Death,” Bioorg. Med. Chem. 9:1371-1384, 2001.
Boyd, M. R. et al., “Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen,” Drug Dev. Res. 34:91-109, 1995.
Bundgaard, H., “(C) Means to Enhance Penetration: (1) Prodrugs as a Means to Improve the Delivery of Peptide Drugs,” Adv. Drug Deliv. Rev. 8:1-38, 1992.
Bundgaard, H., “Design of Prodrugs,” In:Methods in Ezymology, K. Widder et al., Eds., Academic Press, Elsevier, pp. 309-396, 1985.
Bundgaard, H., “Design and Application of Prodrugs,” Chapter 5, In:A Textbook of Drug Design and Development, Krosgaard et al., Eds., pp. 113-191, 1991.
Cannon-Albright, L. A. et al., “Assignment of a Locus for Familial Melanoma, MLM, to Chromosome 9p13-p22,” Science 258:1148-1152, Nov. 13, 1992.
Cossarizza, A. et al., “Analysis of Mitochondria During Cell Death,” Methods Cell Biol. 63:467-486, 2001.
de Graaff, M. et al., “In Vitro Antagonistic Cytotoxic Interactions Between Platinum Drugs and Taxanes on Bone Marrow Progenitor Cell CFU-GM,” Anti-Cancer Drugs 10:213-218, 1999.
Fountain, J. W. et al., “Homozygous Deletions Within Human Chromosome Band 9p21 in Melanoma,” Proc. Natl. Acad. Sci. 89(21):10557-10561, Nov. 1, 1992.
Gallagher, R. et al., “Characterization of the Continuous, Differentiating Myeloid Cell Line (HL-60) from a Patient with Acute Promyelocytic Leukemia,” Blood 54(3):713-733, Sep. 1979.
Grever, M. R. et al., “The National Cancer Institute: Cancer Drug Discovery and Development Program,” Sem. Oncol. 19(6):622-638, Dec. 1992.
Grossman, D. et al.,“Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma,” J. Invest. Dermatol. 113:1076-1081, 1999.
Hanahan, D. et al., “The Hallmarks of Cancer,” Cell 100:57-70, Jan. 7, 2000.
Hartmann, A. et al., “Caspase-3: A Vulnerability Factor and Final Effector in Apoptotic Death of Dopaminergic Neurons in Parkinson's Disease,” Proc. Natl. Acad. Sci. 97(6):2875-2880, Mar. 14, 2000.
Haskell, C.M.,Cancer Treatment, 1stEdition, W.B. Saunders Company, pp. 62-87, 1980.
Haskell, C.M.,Cancer Treatment, 3rdEdition, W.B. Saunders Company, pp. 62-87, 1991.
Haskell, C.M.,Cancer Treatment, 5thEdition, W.B. Saunders Company, pp. 78-87, 2001.
Helmbach, H. et al., “Drug-Resistance in Human Melanoma,” Int. J. Cancer 93:617-622, 2001.
Hwang, S.-Y. et al., “N-Phenethy1-2-Phenylacetamide Isolated fromXenorhabdus nematophilusInduces Apoptosis Through Caspase Activation and Calpain-Mediated Bax Cleavage in U937 Cells,” Int. J. Oncol. 22:151-157, 2003.
Hwang, Z., “The Chemical Biology of Apoptosis: Exploring Protein-Protein Interactions and the Life and Death of Cells with Small Molecules,” Chem Biol. 9:1059-1072, Oct. 2002.
Jemal, A. et al., “Cancer Statistics, 2002,” CA Cancer J. Clin. 52:23-47, 2002.
Jeong, H.-J. et al., “Aromatase Inhibitors fromIsodon excisusvar.coreanus,” Arch. Pharm. Res. 23(3):243-245, 2000.
Johnstone, R. W. et al., “Apoptosis: A Link Between Cancer Genetics and Chemotherapy,” Cell 108:153-164, Jan. 25, 2002.
Khan, K. M. et al., “Three Tyrosinase Inhibitors and Antioxidant Compounds fromSalsola foetida,” Helvetica Chimica Acta 86:457-464, 2003.
Konstantinov, S. M. et al., “Alkylphosphocholines: Effects on Human Leukemic Cell Lines and Normal Bone Marrow Cells,” Int. J. Cancer 77:778-786, 1998.
Lee, C. et al., “Agastinol and Agastenol, Novel Lignans fromAgastache rugosaand Their Evaluation in an Apoptosis Inhibition Assay,” J. Nat. Prod. 65:414-416, 2002.
Lee, C. et al., “Two New Constituents ofIsodon excisusand Their Evaluation in an Apoptosis Inhibition Assay,” J. Nat. Prod. 64:659-660, 2001.
Lev, D. C. et al., “Exposure of Melanoma Cells to Dacarbazine Results in Enhanced Tumor Growth and Metastasis In Vivo,” J. Clin. Oncol. 22(11):2092-2100, Jun. 1, 2004.
Li, Q. et al., “Immunotoxicity of N,N-Diethylaniline in Mice: Effect on Natural Killer Activity, Cytotoxic T Lymphocyte Activity, Lymphocyte Proliferation Response and Cellular Components of the Spleen,” Toxicology 150:179-189, 2000.
LoRusso, P. M. et al., “Preclinical Antitumor Activity of XK469 (NSC 656889),” Invest. New Drugs 16:287-296, 1999.
Makin, G. et al., “Recent Advances in Understanding Apoptosis: New Therapeutic Opportunities in Cancer Chemotherapy,” Trends Mol. Med. 9(6):251-255, Jun. 2003.
Marx, J., “New Leads on the ‘How’ of Alzheimer's,” Science 293:2192-2194, Sep. 21, 2001.
Mattson, M. P., “Apoptosis in Neurodegenerative Disorders,” Nat. Rev. Mol. Cell Biol. 1:120-129, Nov. 2000.
McGovern, V. J. et al., “Pathology of Melanoma: An Overview,” Chapter 3, In:Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide, C. M. Balch et al., Eds., J. B. Lippincott Co., Philadelphia, pp. 29-53, 1985.
Middleton, M. R. et al., “A Randomized Phase III Study Comparing Dacarbazine, BCNU, Cisplatin and Tamoxifen with Dacarbazine and Inerferon in Advanced Melanoma,” Br. J. Cancer 82(6):1158-1162, 2000.
Monks, A. et al., “The NCI Anti-Cancer Drug Screen: A Smart Screen
Allen Brittany Joy
Dothager Robin Shane
Hergenrother Paul J.
Leslie Benjamin James
Nesterenko Vitaliy
Greenlee Winner and Sullivan P.C.
Kumar Shailendra
The Board of Trustees of the University of Illionis
LandOfFree
Compounds and methods for treatment of cancer and modulation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for treatment of cancer and modulation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treatment of cancer and modulation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068331